Ataxia-telangiectasia (A-T) is a rare, progressive, multi-system disorder caused by a gene mutation. It is characterized by a combination of neurological, immunological, and ocular abnormalities.
The neurological symptoms of A-T are ataxia—loss of coordination—of head and limbs, and choreoathetosis—involuntary, jerky movements. Other neurological symptoms include difficulty walking, balance problems, tremors, dysarthria, and difficulty with fine motor activities. In addition, individuals with A-T may experience a general decrease in muscle tone, which can lead to muscle weakness and poor posture.
Immunological manifestations of A-T include elevated levels of IgA, IgM, and IgG. This can lead to recurrent bacterial and viral infections. A-T patients may also experience increased sensitivity to radiotherapy and chemotherapy.
Ocular manifestations of A-T include telangiectasia—dilation of the blood vessels—in the eyes, which can lead to dry eyes, photophobia, and decreased vision. Other ocular symptoms can include strabismus, anisometropia, and astigmatism.
A-T is associated with other systemic manifestations such as diabetes, hypothyroidism, and an increased risk of cancer. Patients may also experience some degree of cognitive impairment, including difficulty with language, memory, and attention.
Due to the progressive nature of A-T, individuals may experience an overall decline in physical and cognitive functioning over time. It is important for patients with A-T to receive regular medical monitoring to track the progression of the disease and to receive appropriate interventions to maintain their quality of life.